The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Phase I trial of nintedanib and chemotherapy in metastatic PDAC
Salwan Al Mutar, MD, UT Southwestern Medical Center, Dallas, TX, explores a Phase Ib study (NCT02902484) of nintedanib, an oral kinase inhibitor targeting VEGFR, PDGFR, and FGFR, with gemcitabine and nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (PDAC). Results showed that nintedanib 200 mg twice daily was safe and tolerable and the most common adverse events included anemia, neuropathy, and fatigue. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
